Jefferies analyst Chris Howerton downgraded MEI Pharma to Underperform from Hold with a price target of 10c, down from 40c, citing what the firm views as an unfavorable risk-reward given sector sentiment and capital risk.
Published first on TheFly
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
